CY1124369T1 - Συνθεση εμφυτευματος ρισπεριδονης ή/και παλιπεριδονης - Google Patents

Συνθεση εμφυτευματος ρισπεριδονης ή/και παλιπεριδονης

Info

Publication number
CY1124369T1
CY1124369T1 CY20211100644T CY211100644T CY1124369T1 CY 1124369 T1 CY1124369 T1 CY 1124369T1 CY 20211100644 T CY20211100644 T CY 20211100644T CY 211100644 T CY211100644 T CY 211100644T CY 1124369 T1 CY1124369 T1 CY 1124369T1
Authority
CY
Cyprus
Prior art keywords
paliperidone
risperidone
weeks
glycolic acid
lactic
Prior art date
Application number
CY20211100644T
Other languages
Greek (el)
English (en)
Inventor
Ibon Gutierro Aduriz
Guillermo Franco Rodríguez
Original Assignee
Laboratorios Farmaceuticos Rovi, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46147376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1124369(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2011/059000 external-priority patent/WO2011151355A1/en
Priority claimed from PCT/EP2011/059001 external-priority patent/WO2011151356A2/en
Application filed by Laboratorios Farmaceuticos Rovi, S.A. filed Critical Laboratorios Farmaceuticos Rovi, S.A.
Publication of CY1124369T1 publication Critical patent/CY1124369T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CY20211100644T 2011-05-31 2021-07-16 Συνθεση εμφυτευματος ρισπεριδονης ή/και παλιπεριδονης CY1124369T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2011/059000 WO2011151355A1 (en) 2010-05-31 2011-05-31 Antipsychotic injectable depot composition
PCT/EP2011/059001 WO2011151356A2 (en) 2010-05-31 2011-05-31 Methods for the preparation of injectable depot compositions
EP12170362.3A EP2529756B1 (en) 2011-05-31 2012-05-31 Risperidone and/or Paliperidone implant formulation

Publications (1)

Publication Number Publication Date
CY1124369T1 true CY1124369T1 (el) 2022-07-22

Family

ID=46147376

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100644T CY1124369T1 (el) 2011-05-31 2021-07-16 Συνθεση εμφυτευματος ρισπεριδονης ή/και παλιπεριδονης

Country Status (32)

Country Link
EP (2) EP2529756B1 (https=)
JP (1) JP6367795B2 (https=)
KR (1) KR101880716B1 (https=)
CN (1) CN104363923A (https=)
AU (1) AU2013269547B2 (https=)
BR (1) BR112014029209A2 (https=)
CA (1) CA2874765C (https=)
CL (1) CL2014003216A1 (https=)
CO (1) CO7160108A2 (https=)
CY (1) CY1124369T1 (https=)
DK (2) DK2529756T3 (https=)
EA (1) EA031819B1 (https=)
ES (1) ES2878112T3 (https=)
FI (1) FI2854858T3 (https=)
HR (2) HRP20260301T1 (https=)
IL (1) IL235849B (https=)
IN (1) IN2014DN10672A (https=)
LT (2) LT2529756T (https=)
MA (1) MA37664B1 (https=)
MX (1) MX374955B (https=)
MY (1) MY174999A (https=)
NZ (1) NZ703321A (https=)
PH (1) PH12014502667B1 (https=)
PL (2) PL2529756T3 (https=)
PT (2) PT2529756T (https=)
RS (1) RS62059B1 (https=)
SG (1) SG11201407961WA (https=)
SI (1) SI2529756T1 (https=)
SM (1) SMT202100448T1 (https=)
UA (1) UA119430C2 (https=)
WO (1) WO2013178812A1 (https=)
ZA (1) ZA201409299B (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
EP2529757B1 (en) * 2011-05-31 2014-01-08 Laboratorios Farmaceuticos Rovi, S.A. Paliperidone implant formulation
US10881605B2 (en) 2010-05-31 2021-01-05 Laboratorios Farmaceuticos Rovi, S.A. Methods for the preparation of injectable depot compositions
US10463607B2 (en) 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
LT2394664T (lt) 2010-05-31 2016-09-26 Laboratorios Farmaceuticos Rovi, S.A. Antipsichozinė injekcinė depozitinė kompozicija
PT2394663T (pt) 2010-05-31 2021-11-26 Farm Rovi Lab Sa Composições para implantes biodegradáveis injectáveis
LT2529756T (lt) * 2011-05-31 2021-07-26 Laboratorios Farmaceuticos Rovi, S.A. Risperidono ir (arba) paliperidono implantų kompozicija
HK1220628A1 (zh) 2013-03-11 2017-05-12 Durect Corporation 包含高粘度液体载体的可注射控制释放组合物
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
CN104922085B (zh) * 2015-06-01 2016-10-26 湖南赛沃药业有限公司 一种利培酮植入剂及其制备方法
CN109589304A (zh) * 2017-10-01 2019-04-09 万特制药(海南)有限公司 利培酮口服溶液及其制备方法
US11689849B2 (en) 2018-05-24 2023-06-27 Nureva, Inc. Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones
KR20260007295A (ko) 2018-05-24 2026-01-13 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치
US11690806B2 (en) 2018-05-24 2023-07-04 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
PE20210047A1 (es) 2018-06-12 2021-01-08 Farm Rovi Lab Sa Composicion inyectable
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
US12594236B2 (en) 2021-07-16 2026-04-07 Laboratorios Farmaceuticos Rovi, S.A. Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition
US12318387B2 (en) 2021-07-16 2025-06-03 Laboratorios Farmaceuticos Rovi, S.A. Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition
TW202313047A (zh) 2021-09-21 2023-04-01 西班牙商禾霏藥品實驗室有限公司 抗精神病可注射儲積型組合物
AU2023281232A1 (en) 2022-05-18 2024-10-24 Laboratorios Farmacéuticos Rovi, S.A. Prolonged-release injectable compositions for use in treatment with risperidone together with cyp2d6 enzyme inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1074923C (zh) 1993-11-19 2001-11-21 詹森药业有限公司 微囊密封的3-哌啶基取代的1,2-苯并异唑类和1,2-苯并异噻唑类
US7658998B2 (en) * 2003-01-22 2010-02-09 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
WO2005007122A2 (en) * 2003-07-18 2005-01-27 Oakwood Laboratories, L.L.C. Polymer stabilization
JP2008509144A (ja) 2004-08-04 2008-03-27 アルザ・コーポレーシヨン 上昇するゼロ次放出パターンを示す持続薬剤放出組成物、そのような組成物を製造する方法
JP5315336B2 (ja) 2007-04-19 2013-10-16 又欣 李 精神疾患治療用の新規化合物とその調剤及び使用
DK2167039T3 (en) * 2007-05-18 2017-01-09 Durect Corp Improved depot formulations
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
WO2009015828A1 (en) 2007-07-27 2009-02-05 Synthon B.V. Paliperidone derivatives
BRPI0821408A2 (pt) 2007-12-19 2015-06-16 Janssen Pharmaceutica Nv Regime de dosagem associado a ésteres de paliperidona injetáveis de longa ação
EP2485712A1 (en) 2009-10-06 2012-08-15 Ascendis Pharma A/S Subcutaneous paliperidone composition
EP2529757B1 (en) * 2011-05-31 2014-01-08 Laboratorios Farmaceuticos Rovi, S.A. Paliperidone implant formulation
LT2394664T (lt) 2010-05-31 2016-09-26 Laboratorios Farmaceuticos Rovi, S.A. Antipsichozinė injekcinė depozitinė kompozicija
PT2394663T (pt) * 2010-05-31 2021-11-26 Farm Rovi Lab Sa Composições para implantes biodegradáveis injectáveis
LT2529756T (lt) * 2011-05-31 2021-07-26 Laboratorios Farmaceuticos Rovi, S.A. Risperidono ir (arba) paliperidono implantų kompozicija

Also Published As

Publication number Publication date
CA2874765A1 (en) 2013-12-05
JP6367795B2 (ja) 2018-08-01
ZA201409299B (en) 2015-12-23
SI2529756T1 (sl) 2021-09-30
PH12014502667B1 (en) 2020-01-22
HRP20260301T1 (hr) 2026-04-10
SG11201407961WA (en) 2014-12-30
IN2014DN10672A (https=) 2015-08-28
BR112014029209A2 (pt) 2017-06-27
PT2529756T (pt) 2021-07-28
EA031819B1 (ru) 2019-02-28
HRP20211057T1 (hr) 2021-10-01
PH12014502667A1 (en) 2015-02-02
KR20150016964A (ko) 2015-02-13
MX374955B (es) 2025-03-06
CN104363923A (zh) 2015-02-18
LT2529756T (lt) 2021-07-26
CL2014003216A1 (es) 2015-07-10
EP2529756A3 (en) 2013-08-07
EP2854858B1 (en) 2025-12-10
CO7160108A2 (es) 2015-01-15
EA201401346A1 (ru) 2015-04-30
RS62059B1 (sr) 2021-07-30
PL2854858T3 (pl) 2026-04-20
AU2013269547B2 (en) 2018-03-15
CA2874765C (en) 2020-06-02
AU2013269547A1 (en) 2015-01-22
DK2529756T3 (da) 2021-08-02
IL235849B (en) 2019-03-31
EP2529756B1 (en) 2021-05-19
MY174999A (en) 2020-06-01
EP2529756A2 (en) 2012-12-05
MA37664B1 (fr) 2016-11-30
WO2013178812A1 (en) 2013-12-05
NZ703321A (en) 2017-01-27
KR101880716B1 (ko) 2018-08-17
UA119430C2 (uk) 2019-06-25
SMT202100448T1 (it) 2021-09-14
PL2529756T3 (pl) 2021-11-15
EP2854858A1 (en) 2015-04-08
MX2014014483A (es) 2015-02-24
IL235849A0 (en) 2015-01-29
PT2854858T (pt) 2026-03-06
FI2854858T3 (fi) 2026-03-03
LT2854858T (lt) 2026-03-10
MA37664A1 (fr) 2016-03-31
ES2878112T3 (es) 2021-11-18
JP2015518036A (ja) 2015-06-25
DK2854858T3 (da) 2026-03-09

Similar Documents

Publication Publication Date Title
CY1124369T1 (el) Συνθεση εμφυτευματος ρισπεριδονης ή/και παλιπεριδονης
EA201401348A1 (ru) Технология приготовления имплантируемой формы палиперидона
CY1123370T1 (el) Σταθερη ενεσιμη φαρμακευτικη συνθεση ανταγωνιστη υποδοχεα νευροκινινης 1 και μεθοδος παρασκευης αυτης
CY1122771T1 (el) Φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης για τη χορηγηση πρωτεϊνων στον οφθαλμο και μεθοδοι για την παρασκευη αυτων
CY1120975T1 (el) Συστημα αποθεματος που περιλαμβανει οξικη γλατιραμερη
CY1124037T1 (el) Παρασκευη φορτωμενων με πεπτιδιο μικροσφαιριδιων plga me χαρακτηριστικα ελεγχομενης απελευθερωσης
CY1118183T1 (el) Φαρμακευτικη μορφη δοσης η οποια περιεχει νιφεδιπινη ή νισολδιπινη και εναν ανταγωνιστη αγγειοτενσινης ιι ή/και ενα διουρητικο
AR088250A1 (es) Forma de dosificacion farmaceutica oral resistente a alteracion comprendiendo agonista opioide y antagonista opioide
CY1125157T1 (el) Ενεσιμες συνθεσεις που εμπεριεχουν λετροζολη ή αναστροζολη
CY1117964T1 (el) Αντιψυχωτικη ενεσιμη συνθεση μακρας διαρκειας δρασης τεχνικος τομεας
EP4647126A3 (en) Stabilizing camptothecin pharmaceutical compositions
SA517381298B1 (ar) تركيبة صيدلية بثبات محسن
NZ766474A (en) Long-acting injectable formulations and crystalline forms of buprenorphine derivatives
PH12017502149A1 (en) Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
CY1113140T1 (el) Στερεα μορφη δοσης απο του στοματος, που περιεχει τον αντιαιμοπεταλιακο παραγοντα κλοπιδογρελη, και μεθοδος για την παρασκευη αυτης
BR112018017005A2 (pt) composto derivado de entecavir e composição farmacêutica para prevenir ou tratar hepatite b
TH159015A (th) ริสเพอริโดนหรือสูตรตำรับในการปลูกถ่ายพาลิเพอริโดน